Satoshi Sogabe

Satoshi Sogabe

Auto-generated profile, based on publicly available information

Satoshi Sogabe

Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2012 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
SSSatoshi Sogabe
Satoshi Sogabe
YKYouichi Kawakita
Youichi Kawakita
SIShigeru Igaki
Shigeru Igaki
HIHidehisa Iwata
Hidehisa Iwata
HMHiroshi Miki
Hiroshi Miki
TITomoyasu Ishikawa
Tomoyasu Ishikawa

15 May 2017 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
SSSatoshi Sogabe
Satoshi Sogabe
YKYusuke Kamada
Yusuke Kamada
MMMasanori Miwa
Masanori Miwa
ANAyumu Niida
Ayumu Niida
TSTomoya Sameshima
Tomoya Sameshima
KSKotaro Sakamoto
Kotaro Sakamoto

25 September 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JAJumpei Aida
Jumpei Aida
MFMakoto Fushimi
Makoto Fushimi
TKTomokazu Kusumoto
Tomokazu Kusumoto
HSHideyuki Sugiyama
Hideyuki Sugiyama
NANaoto Arimura
Naoto Arimura
TKTatsuki Koike
Tatsuki Koike

30 July 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
SIShuhei Ikeda
Shuhei Ikeda
HSHideyuki Sugiyama
Hideyuki Sugiyama
HTHidekazu Tokuhara
Hidekazu Tokuhara
MMMasataka Murakami
Masataka Murakami
MNMinoru Nakamura
Minoru Nakamura
MKMakoto Kamata
Makoto Kamata
The therapeutic potential of monoacylglycerol lipase (MAGL) inhibitors in central nervous system-related diseases has attracted attention worldwide. However, the availability of reversible-type inhibitor is still limited to clarify the pharmacological effect. Herein, we report the discovery of novel spiro chemical series as potent and reversible MAGL inhibitors with a different binding mode to MAGL using Arg57 and His121. Starting from hit compound 1 and its co-crystal structure with MAGL, structure-based drug discovery (SBDD) approach enabled us to generate various spiro scaffolds like 2a (azetidine-lactam), 2b (cyclobutane-lactam), and 2d (cyclobutane-carbamate) as novel bioisosteres of 3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl moiety in 1 with higher lipophilic ligand efficiency (LLE). Optimization of the left hand side afforded 4f as a promising reversible MAGL inhibitor, which showed potent in vitro MAGL inhibitory activity (IC50 6.2 nM), good oral absorption, blood–brain barrier penetration, and significant pharmacodynamic changes (2-arachidonoylglycerol increase and arachidonic acid decrease) at 0.3–10 mg/kg, po. in mice.

1 October 2014 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
THTomoaki Hasui
Tomoaki Hasui
NONorio Ohyabu
Norio Ohyabu
TOTaiichi Ohra
Taiichi Ohra
KFKoji Fuji
Koji Fuji
TSTakahiro Sugimoto
Takahiro Sugimoto
SFShoji Fukumoto
Shoji Fukumoto

7 February 2018 in Biochemistry
Verified
Journal Article
Closed access
TSTomoya Sameshima
Tomoya Sameshima
TYTakeshi Yamamoto
Takeshi Yamamoto
OSOsamu Sano
Osamu Sano
SSSatoshi Sogabe
Satoshi Sogabe
SIShigeru Igaki
Shigeru Igaki
IMIkuo Miyahisa
Ikuo Miyahisa